External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort - Abstract

PURPOSE: The Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S) score predicts prostate cancer (PCa) recurrence based on pathologic information from radical prostatectomy (RP).

CAPRA-S has never been externally validated in a European cohort. We independently validated the CAPRA-S in a European, single-institution database.

MATERIALS AND METHODS: The study cohort comprised of 14532 patients treated with radical prostatectomy between January 1992 and August 2012. Prediction of biochemical recurrence (BCR), metastasis and cancer-specific mortality (CSM) by CAPRA-S was assessed by Kaplan-Meier analysis and the c-index. Performance of CAPRA-S in predicting BCR was assessed by calibration plot and decision curve analysis.

RESULTS: Median follow up was 50.8 months (IQR 25.0 - 96.0). BCR occurred in 20.3% of men at a median time of 21.2 mo (IQR 7.7 - 44.9). When stratifying patients by CAPRA-S risk groups, BCR-free survival estimates at 5 years were 91.4%, 70.4%, and 29.3% for the low, intermediate and high-risk group, respectively. The c-index for CAPRA-S in predicting BCR was 0.80. The c-indices for CAPRA-S in predicting metastasis and CSM were 0.85 and 0.88, respectively. 417 men developed metastasis, and 196 men died from PCa.

CONCLUSIONS: The postoperative CAPRA-S score was accurate when applied in a European study cohort and predicted biochemical recurrence, metastasis and CSM after RP with c-indices > 0.80. The score can be valuable for decision-making for adjuvant therapy.

Written by:
Tilki D, Mandel P, Schlomm T, Chun FK, Tennstedt P, Pehrke D, Haese A, Huland H, Graefen M, Salomon G.   Are you the author?
Martini-Clinic Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.  

Reference: J Urol. 2014 Dec 10. pii: S0022-5347(14)05061-7.
doi: 10.1016/j.juro.2014.12.020

PubMed Abstract
PMID: 25498570

UroToday.com Prostate Cancer Section


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.